ReviewCurrent opinion in organ transplantation2010
Deciphering antibody-mediated rejection: new insights into mechanisms and treatment.
Review in Current opinion in organ transplantation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 115 citations in OpenAlex.
- Weak Expression of Terminal Complement in Active Antibody-Mediated Rejection of the Kidney.Frontiers in immunology · 2022Article
- The five dimensions of B cell tolerance.Immunological reviews · 2019Review
- Complement-Mediated Enhancement of Monocyte Adhesion to Endothelial Cells by HLA Antibodies, and Blockade by a Specific Inhibitor of the Classical Complement Cascade, TNT003.Transplantation · 2017Article
- Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field.European journal of clinical pharmacology · 2016Article
- Reversing endogenous alloreactive B cell GC responses with anti-CD154 or CTLA-4Ig.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2013Article
- Transplantation: The promise of co-stimulatory blockade in transplantation.Nature reviews. Nephrology · 2013Article
- Renal allografts in plasma cell myeloma hematopoietic cell graft recipients: on the verge of an explosion?Bone marrow transplantation · 2013Review
- The paradoxical functions of B cells and antibodies in transplantation.Journal of immunology (Baltimore, Md. : 1950) · 2013Review
- HLA class I: an unexpected role in integrin β4 signaling in endothelial cells.Human immunology · 2012Review
- The role of HLA antibodies in allogeneic SCT: is the 'type-and-screen' strategy necessary not only for blood type but also for HLA?Bone marrow transplantation · 2012Review
- Application of systems biology principles to protein biomarker discovery: urinary exosomal proteome in renal transplantation.Proteomics. Clinical applications · 2012Article
- The impact of donor-specific anti-HLA antibodies on late kidney allograft failure.Nature reviews. Nephrology · 2012Review
- Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation.Blood · 2011Article
- Acute rejection associated with donor-specific anti-MICA antibody in a highly sensitized pediatric renal transplant recipient.Pediatric transplantation · 2011Article
- Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs.Gastroenterology · 2011Review
- HLA class I molecules partner with integrin β4 to stimulate endothelial cell proliferation and migration.Science signaling · 2010Article
- Bortezomib in kidney transplantation.Journal of transplantation · 2010Article
- Review
- Review
Corrections and comments
- Commented on by
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo outline recent studies describing the mechanisms of antibody-mediated rejection (AMR) and new clinical protocols aimed at prevention and/or treatment of this difficult clinical entity. RECENT
findingsThe natural history of acute AMR after positive cross-match kidney transplantation involves an acute rise in donor-specific alloantibody (DSA) in the first few weeks after transplantation. Whereas the exact cellular mechanisms responsible for AMR are not known, it seems likely that both pre-existing plasma cells and the conversion of memory B cells to new plasma cells play a role in the increased DSA production. One recent study suggested that combination therapy with plasmapheresis, high-dose IVIG and rituximab was more effective treatment for AMR than high-dose intravenous immunoglobulin (IVIG) alone, but the role of anti-CD20 antibody is still unclear. Two new promising approaches to AMR focus on depletion of plasma cells with the proteasome inhibitor, bortezomib, and the inhibition of terminal complement activation with a humanized, anti-C5 antibody, eculizumab. SUMMARY: The pathogenesis of AMR in several different clinical settings is becoming clearer and more effective treatments are being developed. Whether the prevention or successful treatment of AMR will decrease the prevalence of chronic injury and improved long-term graft survival will require longer-term studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.